Trial Profile
Phase I Study of Itacitinib in Combination With Tocilizumab for the Treatment of Steroid Refractory Acute Graft Versus Host Disease
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 15 May 2023
Price :
$35
*
At a glance
- Drugs Itacitinib (Primary) ; Tocilizumab (Primary)
- Indications Graft-versus-host disease
- Focus Adverse reactions
- Acronyms GVHD
- 09 May 2023 Status changed from recruiting to discontinued.
- 28 Apr 2022 Planned End Date changed from 1 May 2022 to 1 May 2024.
- 28 Apr 2022 Planned primary completion date changed from 1 May 2022 to 1 May 2024.